Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per share

Loss per share	6 Months Ended
Jun. 30, 2021
Loss per share
Loss per share	Note 4 — Loss per share The dilutive effect of 113,659,553 and 89,998,033 stock options outstanding as of June 30, 2021 and 2020 respectively have been excluded from the diluted loss per share calculation for the three and six months ended June 30, 2021 and 2020, because they would have an antidilutive effect on the loss per share for the period.

Loss per share

6 Months Ended

Jun. 30, 2021

Note 4 — Loss per share

The dilutive effect of 113,659,553 and 89,998,033 stock options outstanding as of June 30, 2021 and 2020 respectively have been excluded from the diluted loss per share calculation for the three and six months ended June 30, 2021 and 2020, because they would have an antidilutive effect on the loss per share for the period.